Sector: Health Care
Director information for PFIZER INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Albert Bourla | Chairman and CEO | 64 | ["30 years of leadership experience","Expertise in medicine and science","Experience in global healthcare and regulatory environment","Former COO of Pfizer","President and General Manager of Established Products Business Unit of Pfizer"] | ["Board of Pharmaceutical Research and Manufacturers of America (PhRMA)","The Pfizer Foundation","Partnership for New York City","Catalyst"] | 2026 |
| Albert Bourla | DVM, Ph.D. | 64 | [] | [] | 2026 |
| Chris Boshoff | Chief Scientific Officer and President | ["Led the transformation of Pfizer’s global R&D organization","Enhanced strategic focus, operational excellence and scientific productivity","Unified Pfizer’s global R&D organization","Established four end-to-end R&D units","Achieved transformative business development and AI-driven innovation"] | [] | 2026 | |
| Cyrus Taraporevala | President and Chief Executive Officer; Committee Member | 59 | ["Business Leadership","Operations","Finance & Accounting","International Business","Risk Management","Human Capital Management","Independent","Financially Literate","Audit Committee Financial Expert"] | ["Audit","Compensation","Audit Committee"] | 2026 |
| Dan R. Littman | Committee Member | [] | ["Science and Technology Committee"] | 2026 | |
| Dan R. Littman, MD, Ph.D. | Director | 73 | ["Significant achievements in medicine, healthcare and academia","Faculty member at NYU Langone Medical Center for more than 25 years","Renowned immunologist and molecular biologist","Member of the National Academy of the Sciences","Member of the National Academy of Medicine","Fellow of the American Academy of Arts and Sciences","Fellow of the American Academy of Microbiology","Scientific co-founder and Advisory Board Member of Vedanta Biosciences and Immunai, Inc."] | ["Governance","Audit","Regulatory and Compliance","Science and Technology","Governance Committee","Regulatory and Compliance Committee"] | 2026 |
| Douglas M. Lankler | Chief Legal Officer, EVP | ["Provided legal advice and counsel on Pfizer’s legal matters","Executed key business development transactions","Achieved favorable resolutions in intellectual property litigation","Provided legal leadership in negotiating agreements with the U.S. Government","Provided support for R&D and Commercial organizational changes"] | [] | 2026 | |
| James C. Smith | Chairman of the Board; Committee Member | 66 | ["Chair","Business Leadership","Operations","Finance","Accounting","International Business","Human Capital Management","Risk Management","Independent","Financially Literate","Audit Committee Financial Expert"] | ["Audit","Compensation","Audit Committee"] | 2026 |
| James Quincey | Chairman and Chief Executive Officer | 61 | ["Business Leadership & Operations","Finance & Accounting","International Business","Human Capital Management","Technology & Cybersecurity"] | ["Compensation"] | 2026 |
| Joseph J. Echevarria | President and CEO of the University of Miami; Committee Member; Chairman of the Governance Committee | 69 | ["Chair","Business Leadership & Operations","Finance & Accounting","International Business","Risk Management","Government & Public Policy","Independent","Financially Literate","Audit Committee Financial Expert"] | ["Audit","Governance","Audit Committee"] | 2026 |
| Mortimer J. Buckley | Chairman and Chief Executive Officer; Committee Member | 56 | ["Compensation","Business Leadership & Operations","Finance & Accounting","International Business","Risk Management","Human Capital Management","Technology & Cybersecurity","Independent","Financially Literate","Audit Committee Financial Expert"] | ["Audit","Governance","Audit Committee","Governance Committee"] | 2026 |
| Ronald E. Blaylock | Director; Committee Member | 66 | ["Business Leadership & Operations","Finance & Accounting","Risk Management","Independent","Financially Literate","Audit Committee Financial Expert"] | ["Audit","Compensation","Audit Committee"] | 2026 |
| Scott Gottlieb | Committee Member | [] | ["Science and Technology Committee"] | 2026 | |
| Scott Gottlieb, MD | Director; Chair | 53 | ["Chair","Expertise in health care, public policy, and the biopharmaceutical industry","Experience at the U.S. Food and Drug Administration (FDA)","Partner at New Enterprise Associates, Inc.'s Healthcare Investment Team","Senior Fellow of the American Enterprise Institute since 2019","23rd Commissioner of the FDA from 2017 to 2019","Experience on the boards of directors of Tempus AI, Inc. and Xaira Therapeutics, Inc."] | ["Regulatory and Compliance","Science and Technology","Regulatory and Compliance Committee"] | 2026 |
| Shantanu Narayen | Chair and CEO; Lead Independent Director | 62 | ["Business Leadership & Operations","Finance & Accounting","International Business","Human Capital Management","Risk Management","Technology & Cybersecurity","strong leadership skills","risk oversight abilities","deep expertise in technology","innovative product development","global leadership experience"] | [] | 2026 |
| Susan Desmond-Hellmann | Chair | [] | [] | 2026 | |
| Susan Desmond-Hellmann, MD, M.P.H. | Director | 68 | ["Chair","Former Chief Executive Officer of the Bill & Melinda Gates Foundation","Former President of Product Development at Genentech","Chancellor of the University of California, San Francisco (UCSF)","Background in medicine, healthcare, and academia","Senior Advisor at Lazard, Inc. in the Healthcare Group","Senior Advisor at GV (formerly Google Ventures)","Board member of OpenAI, Stand Up To Cancer, and the Integrated Genomics Institute"] | ["Governance","Science and Technology","Governance Committee"] | 2026 |
| Susan Hockfield | Committee Member | [] | ["Science and Technology Committee"] | 2026 | |
| Susan Hockfield, Ph.D. | [] | ["Regulatory and Compliance Committee"] | 2026 | ||
| Suzanne Nora Johnson | Director; Chair of the Audit Committee | 68 | ["Business Leadership & Operations","Finance & Accounting","Healthcare & Pharma","International Business","Risk Management"] | ["Chair","Audit","Regulatory and Compliance","Regulatory and Compliance Committee"] | 2026 |
